2-Chloro-5-Iodobenzoic Acid CAS 19094-56-5 Empagliflozin Intermediate Assay ≥99.0% (HPLC)

2-Chloro-5-Iodobenzoic Acid (CAS: 19094-56-5) can be used as a pharmaceutical intermediate in the synthesis of Empagliflozin (CAS: 864070-44-0). Empagliflozin (trade name Jardiance) is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine. On August 1, 2014, the Food and Drug Administration (FDA) officially approved the drug for the treatment of type 2 diabetes, to improve and control blood glucose of adults. Empagliflozin is the third SGLT-2 inhibiting drugs approved by FDA. Another two SGLT-2 inhibitor drugs, Canagliflozin and Dapagliflozin, belonging to Johnson Pharmaceuticals, AstraZeneca and Bristol-Myers Squibb respectively, are approved by FDA in November 2013 and January 2014 respectively.